Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate

Virology

Volumn 366, Issue 1, 2007, Pages 84-97

  Earl, Patricia L ^a   Americo, Jeffrey L ^a   Wyatt, Linda S ^a   Anne Eller, Leigh ^b   Montefiori, David C ^c   Byrum, Russ ^d   Piatak, Michael ^e   Lifson, Jeffrey D ^e   Rao Amara, Rama ^f   Robinson, Harriet L ^f   Huggins, John W ^g   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d BIOQUAL INC   (United States)

^e SAIC FREDERICK INC   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Monkeypox virus; Recombinant modified vaccinia virus Ankara; Rhesus macaque; SHIV 89.6P; Smallpox

Indexed keywords

CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MONKEYPOX; NONHUMAN; ORTHOPOXVIRUS; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN VIRUS; VIRUS LOAD;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS; PRIMATE DISEASES; PRIMATES; RECOMBINANT PROTEINS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T-LYMPHOCYTES; VACCINIA VIRUS; VIRAL PROTEINS; VIRAL VACCINES;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MONKEYPOX VIRUS; ORTHOPOXVIRUS; POXVIRIDAE; PRIMATES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS ANKARA; VARIOLA VIRUS;

EID: 34548175794     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.02.041     Document Type: Article

References (63)

1. Addo M.M., Altfeld M., Rosenberg E.S., Eldridge R.L., Philips M.N., Habeeb K., Khatri A., Brander C., Robbins G.K., Mazzara G.P., Goulder P.J., and Walker B.D. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc. Natl. Acad Sci. U.S.A. 98 (2001) 1781-1786
2. Aldaz-Carroll L., Whitbeck J.C., Ponce de Leon M., Lou H., Hirao L., Isaacs S.N., Moss B., Eisenberg R.J., and Cohen G.H. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J. Virol. 79 (2005) 6260-6271
3. Aldaz-Carroll L., Whitbeck J.C., Ponce de Leon M., Lou H., Pannell L.K., Lebowitz J., Fogg C., White C.L., Moss B., Cohen G.H., and Eisenberg R.J. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology 341 (2005) 59-71
4. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., and Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996) 94-96
5. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.-L., Grimm B.D., Hulsey M.L., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a mucosal challenge and prevention of AIDS in rhesus macaques by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
6. Amara R.R., Smith J.M., Staprans S.I., Montefiori D.C., Villinger F., Altman J.D., O'Neil S.P., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McNicholl J.M., McClure H.M., Moss B., and Robinson H.L. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76 (2002) 6138-6146
7. Amara R.R., Villinger F., Staprans S.I., Altman J.D., Montefiori D.C., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McClure H.M., Moss B., and Robinson H.L. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 76 (2002) 7625-7631
8. Antoine G., Scheiflinger F., Dorner F., and Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244 (1998) 365-396
9. Anton L.C., Schubert U., Bacik I., Princiotta M.F., Wearsch P.A., Gibbs J., Day P.M., Realini C., Rechsteiner M.C., Bennink J.R., and Yewdell J.W. Intracellular localization of proteasomal degradation of a viral antigen. J. Cell Biol. 146 (1999) 113-124
10. Barouch D.H., Craiu A., Santra S., Egan M.A., Schmitz J.E., Kuroda M.J., Fu T.M., Nam J.H., Wyatt L.S., Lifton M.A., Krivulka G.R., Nickerson C.E., Lord C.I., Moss B., Lewis M.G., Hirsch V.M., Shiver J.W., and Letvin N.L. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J. Virol. 75 (2001) 2462-2467
11. Barouch D.H., Santra S., Kuroda M.J., Schmitz J.E., Plishka R., Buckler-White A., Gaitan A.E., Zin R., Nam J.-H., Wyatt L., Lifton M.A., Nicherson C.E., Moss B., Montefiori D.C., Hirsch V.M., and Letvin N.L. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75 (2001) 5151-5158
12. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., Truitt D.M., Sumida S.M., Kishko M.G., Arthur J.C., Korioth-Schmitz B., Newberg M.H., Gorgone D.A., Lifton M.A., Panicali D.L., Nabel G.J., Letvin N.L., and Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172 (2004) 6290-6297
13. Blanchard T.J., Alcami A., Andrea P., and Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79 (1998) 1159-1167
14. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., Goletti D., Borsetti A., Pace M., Fanales-Belasio E., Ridolfi B., Negri D.R., Sernicola L., Belli R., Corrias F., Macchia I., Leone P., Michelini Z., ten Haaft P., Butto S., Verani P., and Ensoli B. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 19 (2001) 2862-2877
15. Carroll M., and Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in nonhuman mammalian cell line. Virology 244 (1997) 365-369
16. Cline A.N., Bess J.W., Piatak Jr. M., and Lifson J.D. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34 (2005) 303-312
17. Crawford J.M., Earl P.L., Moss B., Reimann K.A., Wyand M.S., Manson K.H., Bilska M., Zhou J.T., Pauza C.D., Parren P.W., Burton D.R., Sodroski J.G., Letvin N.L., and Montefiori D.C. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J. Virol. 73 (1999) 10199-10207
18. Douek D.C., Kwong P.D., and Nabel G.J. The rational design of an AIDS vaccine. Cell 124 (2006) 677-681
19. Drexler I., Heller K., Wahren B., Erfle V., and Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79 Pt 2 (1998) 347-352
20. Earl P.L., Hugin A.W., and Moss B. Removal of cryptic poxvirus transcription termination signals from the human immunodediciency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J. Virol. 64 (1990) 2448-2451
21. Earl P.L., Sugiura W., Montefiori D.C., Broder C.C., Lee S.A., Wild C., Lifson J., and Moss B. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virustType 1 gp140. J. Virol. 75 (2001) 645-653
22. Earl P.L., Wyatt L.S., Montefiori D.C., Bilska M., Woodward R., Markham P.D., Malley J.D., Vogel T.U., Allen T.M., Watkins D.I., Miller N., and Moss B. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 294 (2002) 270-281
23. Earl P.L., Americo J.L., and Moss B. Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J. Virol. 77 (2003) 10684-10688
24. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., Eisenberg R.J., Hartmann C.J., Jackson D.L., Kulesh D.A., Martinez M.J., Miller D.M., Mucker E.M., Shamblin J.D., Zwiers S.H., Huggins J.W., Jahrling P.B., and Moss B. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428 (2004) 182-185
25. Edghill-Smith Y., Bray M., Whitehouse C.A., Miller D., Mucker E., Manischewitz J., King L.R., Robert-Guroff M., Hryniewicz A., Venzon D., Meseda C., Weir J., Nalca A., Livingston V., Wells J., Lewis M.G., Huggins J., Zwiers S.H., Golding H., and Franchini G. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J. Infect Dis. 191 (2005) 372-381
26. Egan M.A., Chong S.Y., Rose N.F., Megati S., Lopez K.J., Schadeck E.B., Johnson J.E., Masood A., Piacente P., Druilhet R.E., Barras P.W., Hasselschwert D.L., Reilly P., Mishkin E.M., Montefiori D.C., Lewis M.G., Clarke D.K., Hendry R.M., Marx P.A., Eldridge J.H., Udem S.A., Israel Z.R., and Rose J.K. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res. Hum. Retroviruses 20 (2004) 989-1004
27. Enserink M. Bioterrorism. In search of a kinder, gentler vaccine. Science 296 (2002) 1594
28. Fenner F., Henderson D.A., Arita I., Jezek Z., and Ladnyi I.D. Smallpox and its eradication (1988), Geneva:, World Health Organization
29. Franchini G., Gurunathan S., Baglyos L., Plotkin S., and Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines 3 (2004) S75-S88
30. Fulginiti V.A., Papier A., Lane J.M., Neff J.M., and Henderson D.A. Smallpox vaccination: a review: Part II. Adverse events. Clin. Infect. Dis. 37 (2003) 251-271
31. Hel Z., Johnson J.M., Tryniszewska E., Tsai W.P., Harrod R., Fullen J., Tartaglia J., and Franchini G. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. Vaccine 20 (2002) 3171-3186
32. Henderson D.A. The looming threat of bioterrorism. Science 283 (1999) 1282-1297
33. Hu S.-L. Non-human primate models for AIDS vaccine research. Curr. Drug Targets-Infect. Dis. 5 (2005) 193-201
34. + lymphocyte depletion in rhesus monkeys. J. Virol. 71 (1997) 4218-4225
35. LeDuc J.W., Damon I., Relman D.A., Huggins J., and Jahrling P.B. Smallpox research activities: U.S. interagency collaboration, 2001. Emerg. Infect. Dis. 8 (2002) 743-745
36. Letvin N.L. Progress toward an HIV vaccine. Annu. Rev. Med. 56 (2005) 213-223
37. Maloy K.J., Erdmann I., Basch V.S., S., Kramps T.A., Zinkernagel R.M., Oehen S., and Kuendig T.M. Intralymphatic immunization enhances DNA vaccination. Proc. Natl. Acad. Sci. 98 (2001) 3203-3299
38. Mascola J.R. Defining the protective antibody response for HIV-1. Curr. Mol. Med. 3 (2003) 209-216
39. Mayr A., and Stickl H. Abstammung, eigenschaften und verwendung des attenuieten vaccinia-stammes MVA. Infection 3 (1975) 6-14
40. Mayr A., Hochstein-Mintzel V., and Stickl H. Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA. Infection 3 (1975) 6-14
41. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72 Pt 5 (1991) 1031-1038
42. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 11341-11348
43. Nigam P., Earl P.L., Americo J.L., Sharma S., Wyatt L.S., Edghill-Spano Y., Chennareddi L.S., Silvera P., Moss B., Robinson H.L., and Amara R.R. DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology 366 (2007) 73-83
44. + T cells by infected dendritic cells in vivo. Nat. Immunol. 3 (2002) 265-271
45. Otten G.R., Schaefer M., Doe B., Liu H., Megede J.Z., Donnelly J., Rabussay D., Barnett S., and Ulmer J.B. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 24 (2006) 4503-4509
46. Ourmanov I., Brown C.R., Moss B., Carroll M., Wyatt L., Pletneva L., Goldstein S., Venzon D., and Hirsch V.M. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) gag-Pol and/or env in macaques challenged with pathogenic SIV. J. Virol. 74 (2000) 2740-2751
47. Peng B., Wang L.R., Gomez-Roman V.R., Davis-Warren A., Montefiori D.C., Kalyanaraman V.S., Venzon D., Zhao J., Kan E., Rowell T.J., Murthy K.K., Srivastava I., Barnett S.W., and Robert-Guroff M. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J. Virol. 79 (2005) 10200-10209
48. Rao S.S., Gomez P., Mascola J.R., Dang V., Krivulka G.R., Yu F., Lord C.I., Shen L., Bailer R., Nabel G.J., and Letvin N.L. Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model. Vaccine 24 (2006) 367-373
49. Reimann K.A., Li J.T., Veazey R., Halloran M., Park I.W., Karlsson G.B., Sodroski J., and Letvin N.L. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70 (1996) 6922-6928
50. Richardson M.W., Mirchandani J., Silvera P., Regulier E.G., Capini C., Bojczuk P.M., Hu J., Gracely E.J., Boyer J.D., Khalili K., Zagury J.F., Lewis M.G., and Rappaport J. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses. DNA Cell Biol. 21 (2002) 637-651
51. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., and Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
52. Sriwanthana B., Hodge T., Mastro T.D., Dezzutti C.S., Bond K., Stephens H.A., Kostrikis L.G., Limpakarnjanarat K., Young N.L., Qari S.H., Lal R.B., Chandanayingyong D., and McNicholl J.M. HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, northern Thailand. AIDS Res. Hum. Retroviruses 17 (2001) 719-734
53. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schafer H., and Holzner A. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch. Med. Wochenschr. 99 (1974) 2386-2392
54. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G.M., van Schalkwijk P., van der Kwast T., Wyatt L.W., Moss B., and Osterhaus A.D.M.E. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19 (2001) 3700-3709
55. Stittelaar K.J., van Amerongen G., Kondova I., Kuiken T., van Lavieren R.F., Pistoor F.H., Niesters H.G., van Doornum G., van der Zeijst B.A., Mateo L., Chaplin P.J., and Osterhaus A.D. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79 (2005) 7845-7851
56. Sugiura W., Broder C.C., Moss B., and Earl P.L. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins. Virology 254 (1999) 257-267
57. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10847-10851
58. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., and Moss B. A recombinant vector derived from the host-range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12 (1994) 1032-1040
59. Van Rompay K.K., Abel K., Lawson J.R., Singh R.P., Schmidt K.A., Evans T., Earl P., Harvey D., Franchini G., Tartaglia J., Montefiori D., Hattangadi S., Moss B., and Marthas M.L. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J. Acquired Immune Defic. Syndr. 38 (2005) 124-134
60. Wang R., Epstein J., Baraceros F.M., Gorak E.J., Charoenvit Y., Carucci D.J., Hedstrom R.C., Rahardjo N., Gay T., Hobart P., Stout R., Jones T.R., Richie T.L., Parker S.E., Doolan D.L., Norman J., and Hoffman S.L. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1022-10817
61. Wyatt L.S., Earl P.L., Eller L.A., and Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 4590-4595
62. Xu R., Srivastava I.K., Kuller L., Zarkikh I., Kraft Z., Fagrouch Z., Letvin N.L., Heeney J.L., Barnett S.W., and Stamatatos L. Immunization with HIV-1 SF162-derived envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology 349 (2006) 276-289
63. Zaucha G.M., Jahrling P.B., Geisbert T.W., Swearengen J.R., and Hensley L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 81 (2001) 1581-1600